Nurix Therapeutics Inc. held its virtual 2025 Annual Meeting of Stockholders on May 19, 2025. During the meeting, stockholders voted on three proposals. The election of directors Judith A. Reinsdorf, Edward C. Saltzman, and Roy D. Baynes was approved. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending November 30, 2025, was ratified. Additionally, the compensation of the company's named executive officers was approved on a non-binding advisory basis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001549595-25-000067), on May 19, 2025, and is solely responsible for the information contained therein.